What are the contraindications for starting Dipeptidyl Peptidase-4 inhibitors (DPP4i) in Diabetes Mellitus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 6, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

DPP-4 inhibitors (DPP4i) should not be initiated in patients with a history of hypersensitivity to these medications or their components, and are contraindicated in patients with a history of pancreatitis or those at high risk for pancreatitis, as well as in patients with heart failure, particularly NYHA class III-IV, due to increased risk of hospitalization, as evidenced by the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus – Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) study 1.

Key Considerations

  • Patients with severe renal impairment require dose adjustments for most DPP4i medications, except linagliptin, as indicated in the diabetes management in chronic kidney disease consensus report 1.
  • DPP4i should be used cautiously in patients with a history of angioedema, especially those taking ACE inhibitors simultaneously, due to the potential for increased risk of angioedema.
  • DPP4i are not recommended during pregnancy or breastfeeding due to limited safety data, as stated in the standards of care in diabetes-2025 report 1.
  • Patients with inflammatory bowel disease or other immune-mediated gastrointestinal disorders should use these medications with caution, as they may potentially exacerbate symptoms.

Additional Guidance

  • The most recent and highest quality study, the standards of care in diabetes-2025 report 1, provides guidance on the use of DPP4i in patients with diabetes mellitus, including considerations for heart failure, renal impairment, and other comorbidities.
  • The diabetes management in chronic kidney disease consensus report 1 provides detailed guidance on dose adjustments for DPP4i in patients with chronic kidney disease.
  • The type 2 diabetes mellitus and heart failure scientific statement from the American Heart Association and the Heart Failure Society of America 1 highlights the importance of careful consideration of DPP4i use in patients with heart failure, particularly those with reduced ejection fraction.

From the FDA Drug Label

CONTRAINDICATIONS Hypersensitivity to linagliptin or any of the excipients in TRADJENTA (4,5. 3)

LIMITATIONS OF USE Not recommended in patients with type 1 diabetes mellitus as it would not be effective (1) Has not been studied in patients with a history of pancreatitis (1)

The contraindications for starting DPP4i (Linagliptin) in diabetes mellitus are:

  • Hypersensitivity to linagliptin or any of the excipients in TRADJENTA
  • Type 1 diabetes mellitus as it would not be effective Additionally, it has not been studied in patients with a history of pancreatitis, so it is not recommended in this population 2

From the Research

Contraindications for Starting DPP4i in Diabetes Mellitus

  • The decision to start DPP4i in patients with diabetes mellitus should be based on individual patient characteristics and medical history, as there are several factors to consider when initiating this treatment 3, 4, 5, 6, 7.
  • Patients with a history of pancreatitis or pancreatic cancer may need to be approached with caution when considering DPP4i therapy, although recent studies suggest that DPP4i may not be associated with an increased risk of pancreatitis or pancreatic cancer 5, 7.
  • DPP4i are generally considered safe and effective for patients with type 2 diabetes mellitus, including those with renal impairment, with the exception of linagliptin, which is eliminated predominantly via the hepatobiliary system 3.
  • However, DPP4i have been associated with an increased risk of heart failure, and patients with a history of heart failure may need to be monitored closely when starting DPP4i therapy 5.
  • The choice of DPP4i should be individualized based on patient characteristics, such as renal function and medical history, as well as the specific properties of each DPP4i, including their pharmacokinetic profiles and potential side effects 4, 6.

Specific Considerations

  • Linagliptin is the exception among DPP4i, as it is eliminated predominantly via the hepatobiliary system, rather than the renal system, making it a potential option for patients with severe renal impairment 3.
  • Sitagliptin has been associated with a significant reduction in pancreatitis risk compared to the control group, and may be a preferred option for patients at high risk of pancreatitis 7.
  • DPP4i have been shown to be effective in improving glycemic control and have a favorable therapeutic profile, making them a useful treatment option for patients with type 2 diabetes mellitus 4, 6.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

3
Research

Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2013

6
Research

The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect.

International journal of environmental research and public health, 2019

Related Questions

What is the most effective DPP-4 (Dipeptidyl Peptidase-4) inhibitor for type 2 diabetes?
What is the role of DPP-4 (Dipeptidyl peptidase-4) inhibitors in antidiabetic treatment?
What are the treatment options for patients with type 2 diabetes using DPP-4 (Dipeptidyl Peptidase-4) inhibitors, such as sitagliptin (Januvia)?
Can glimepiride be taken with glipizide (Glibenclamide)?
Can DDP4 (Dipeptidyl Peptidase-4) inhibitors be used in type 1 diabetes management?
What is the differential diagnosis of granulomatous lesions in a patient with idiopathic thrombocytopenic purpura (ITP) on hydroxychloroquine (Plaquenil) and eltrombopag (Promacta), presenting with asymptomatic facial lesions and diffuse hyperpigmentation, as well as lesions on the anterior aspect of both legs?
What is the likely diagnosis for a 32-year-old male experiencing persistent dizziness, leg weakness, occasional shortness of breath, frequent urination, constant hunger, and dry mouth, following the use of probiotics (probiotic supplements) for two weeks, with normal blood test results and temporary symptom relief after episodes of diarrhea?
What is the evidence for using rituximab, methotrexate (MTX), and infliximab together for the treatment of refractory sarcoidosis?
What is the mechanism of action of Rifaximin (Rifaximin) in the treatment of hepatic encephalopathy?
What is the indication for Magnesium (Mg) supplement?
What is the next step for a monitored patient in the Intensive Care Unit (ICU) who develops a sudden onset of narrow complex tachycardia, specifically supraventricular tachycardia (SVT) at a rate of 220 beats per minute, with hypertension, hypocapnia, and tachypnea, and who has a ventricular access in the left arm, has not received any active medications, and has a 12-lead electrocardiogram (ECG) showing no evidence of ventricular tachycardia, and is not responding to manual maneuvers?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question